Septerna (NASDAQ:SEPN) Stock Price Up 6.7% – Here’s Why

Shares of Septerna, Inc. (NASDAQ:SEPN) were up 6.7% during trading on Wednesday . The stock traded as high as $23.10 and last traded at $23.1540. Approximately 99,459 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 573,105 shares. The stock had previously closed at $21.69.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on SEPN shares. HC Wainwright increased their price target on Septerna from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Wells Fargo & Company upgraded Septerna from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $18.00 to $28.00 in a research note on Friday, November 14th. Wall Street Zen raised Septerna from a “sell” rating to a “buy” rating in a research note on Sunday. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price target on shares of Septerna in a report on Friday, September 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $27.67.

Septerna Price Performance

The stock has a market cap of $1.05 billion and a PE ratio of -15.35. The stock has a 50-day simple moving average of $19.61 and a 200-day simple moving average of $14.06.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.28). Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. The firm had revenue of $21.50 million during the quarter, compared to analyst estimates of $24.50 million. As a group, equities research analysts anticipate that Septerna, Inc. will post -7.11 EPS for the current year.

Insider Activity

In related news, SVP Daniel D. Long sold 3,501 shares of Septerna stock in a transaction on Monday, November 10th. The shares were sold at an average price of $18.06, for a total transaction of $63,228.06. Following the transaction, the senior vice president owned 92,911 shares in the company, valued at approximately $1,677,972.66. The trade was a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.30% of the stock is owned by insiders.

Institutional Trading of Septerna

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new position in shares of Septerna in the third quarter worth about $36,000. Covestor Ltd raised its stake in Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after buying an additional 1,296 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Septerna by 88.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock worth $78,000 after buying an additional 1,945 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Septerna in the 1st quarter worth approximately $49,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares during the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.